Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
03 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/03/3092971/0/en/New-analyses-reinforce-long-term-benefit-of-DARZALEX-daratumumab-subcutaneous-based-quadruplet-regimen-for-patients-with-newly-diagnosed-multiple-myeloma.html
25 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/25/3068097/0/en/TREMFYA-guselkumab-receives-European-Commission-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-Johnson-Johnson-s-leadership-in-inflammatory.html
09 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/european-commission-approved-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility-302424492.html
07 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/07/3056770/0/en/European-Commission-approves-subcutaneous-RYBREVANT-amivantamab-for-the-treatment-of-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer.html
28 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/28/3051280/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-treatment-of-patients-with-moderately-to-severely-active-Crohn-s-Disease.html
26 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/26/3049913/0/en/RYBREVANT-amivantamab-plus-LAZCLUZE-lazertinib-demonstrates-significant-overall-survival-benefit-in-patients-with-EGFR-mutated-advanced-non-small-cell-lung-cancer-versus-osimertini.html
ABOUT THIS PAGE
Janssen-Cilag is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BORGO SAN MICHELE, ITALY bulk offered by Janssen-Cilag